Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 in advanced melanoma
NCT06081920Phase 2Recruiting
- Sponsor
- Innovent Biologics
- Start
- Oct 2023
- Primary completion
- Oct 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI363 in melanoma, sponsored by Innovent Biologics. Started Oct 2023; status: recruiting.
02
Drugs
IBI363
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06081920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081920.